$SWTX
SpringWorks Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000177342722000045 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $40.53M $35.67M
YoY Change 53.21% 97.86%
% of Gross Profit
Research & Development $37.93M $36.07M
YoY Change 29.25% 57.73%
% of Gross Profit
Depreciation & Amortization $255.0K $212.0K
YoY Change 74.66% 78.15%
% of Gross Profit
Operating Expenses $78.45M $71.74M
YoY Change 40.61% 75.42%
Operating Profit -$71.74M
YoY Change 75.42%
Interest Expense $4.123M -$574.0K
YoY Change -1974.09% 552.27%
% of Operating Profit
Other Income/Expense, Net $153.0K $838.0K
YoY Change -373.21% 592.56%
Pretax Income -$74.18M -$72.39M
YoY Change 32.29% 76.38%
Income Tax
% Of Pretax Income
Net Earnings -$74.18M -$72.39M
YoY Change 32.29% 76.38%
Net Earnings / Revenue
Basic Earnings Per Share -$1.37
Diluted Earnings Per Share -$1.19 -$1.368M
COMMON SHARES
Basic Shares Outstanding 62.38M shares 49.44M shares
Diluted Shares Outstanding 52.90M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $592.2M $651.9M
YoY Change 58.56% 52.35%
Cash & Equivalents $67.50M $476.4M
Short-Term Investments $524.7M $175.5M
Other Short-Term Assets $7.548M $5.344M
YoY Change -19.78% 4.76%
Inventory $0.00
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $599.8M $657.3M
YoY Change 56.63% 51.79%
LONG-TERM ASSETS
Property, Plant & Equipment $13.57M $11.48M
YoY Change 325.82% 449.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.193M $4.873M
YoY Change 45.44% 53.05%
Other Assets $2.648M $2.453M
YoY Change -2.25% 0.08%
Total Long-Term Assets $30.48M $24.27M
YoY Change -56.19% -61.02%
TOTAL ASSETS
Total Short-Term Assets $599.8M $657.3M
Total Long-Term Assets $30.48M $24.27M
Total Assets $630.2M $681.6M
YoY Change 39.28% 37.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.010M $4.586M
YoY Change 133.6% 83.59%
Accrued Expenses $39.24M $39.29M
YoY Change 54.63% 61.39%
Deferred Revenue $3.314M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $483.0K $733.0K
YoY Change -58.43% -41.69%
Total Short-Term Liabilities $51.05M $49.49M
YoY Change 70.34% 76.14%
LONG-TERM LIABILITIES
Long-Term Debt $4.768M $5.000M
YoY Change 3596.12% 1262.4%
Other Long-Term Liabilities $16.23M $14.66M
YoY Change 11090.84%
Total Long-Term Liabilities $21.00M $14.66M
YoY Change 11090.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $51.05M $49.49M
Total Long-Term Liabilities $21.00M $14.66M
Total Liabilities $72.05M $69.15M
YoY Change 139.38% 141.82%
SHAREHOLDERS EQUITY
Retained Earnings -$569.9M -$495.8M
YoY Change 94.84% 109.73%
Common Stock $6.000K $6.000K
YoY Change 20.0% 20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $558.2M $612.4M
YoY Change
Total Liabilities & Shareholders Equity $630.2M $681.6M
YoY Change 39.28% 37.61%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$74.18M -$72.39M
YoY Change 32.29% 76.38%
Depreciation, Depletion And Amortization $255.0K $212.0K
YoY Change 74.66% 78.15%
Cash From Operating Activities -$54.20M -$19.60M
YoY Change 17.02% -27.2%
INVESTING ACTIVITIES
Capital Expenditures $1.756M -$3.528M
YoY Change -216.76% 953.13%
Acquisitions
YoY Change
Other Investing Activities -$353.3M $89.76M
YoY Change -712.38% 148.5%
Cash From Investing Activities -$355.0M $86.23M
YoY Change -731.9% 140.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 298.0K 340.2M
YoY Change 22.13% 79954.35%
NET CHANGE
Cash From Operating Activities -54.20M -19.60M
Cash From Investing Activities -355.0M 86.23M
Cash From Financing Activities 298.0K 340.2M
Net Change In Cash -408.9M 406.9M
YoY Change -4145.03% 4283.78%
FREE CASH FLOW
Cash From Operating Activities -$54.20M -$19.60M
Capital Expenditures $1.756M -$3.528M
Free Cash Flow -$55.96M -$16.08M
YoY Change 24.87% -39.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001773427
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39044
dei Entity Registrant Name
EntityRegistrantName
SPRINGWORKS THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-4066827
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Washington Blvd
dei Entity Address City Or Town
EntityAddressCityOrTown
Stamford
dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06902
dei City Area Code
CityAreaCode
203
dei Local Phone Number
LocalPhoneNumber
883-9490
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
SWTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62382266 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
476429000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103961000 usd
CY2022Q3 us-gaap Marketable Securities
MarketableSecurities
175514000 usd
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
269540000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
5344000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
9409000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
657287000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
382910000 usd
CY2022Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0 usd
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
59230000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11482000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3187000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4908000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1010000 usd
CY2022Q3 us-gaap Equity Method Investments
EquityMethodInvestments
4873000 usd
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
2883000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
551000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
565000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2453000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2709000 usd
CY2022Q3 us-gaap Assets
Assets
681554000 usd
CY2021Q4 us-gaap Assets
Assets
452494000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4586000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3429000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
39289000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25378000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
733000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1162000 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4886000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
49494000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29969000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5000000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
129000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14660000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 usd
CY2022Q3 us-gaap Liabilities
Liabilities
69154000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
30098000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62412845 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49247985 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62382646 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49247985 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1111002000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
715216000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-495752000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-292513000 usd
CY2022Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
30199 shares
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0 shares
CY2022Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1341000 usd
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
0 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1515000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-312000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
612400000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
422396000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
681554000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
452494000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36067000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22866000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
108194000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72332000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35673000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18029000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
94026000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
45340000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
71740000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
40895000 usd
us-gaap Operating Expenses
OperatingExpenses
202220000 usd
us-gaap Operating Expenses
OperatingExpenses
117672000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-71740000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-40895000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-202220000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-117672000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-74000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-58000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-291000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-96000 usd
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
912000 usd
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
179000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
1482000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
617000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
838000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
121000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1191000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
521000 usd
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1486000 usd
CY2021Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-267000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2210000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-687000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-72388000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-41041000 usd
us-gaap Net Income Loss
NetIncomeLoss
-203239000 usd
us-gaap Net Income Loss
NetIncomeLoss
-117838000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.37
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.37
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.84
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.84
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-4.04
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-4.04
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.43
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.43
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52900819 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52900819 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48595420 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48595420 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50298015 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50298015 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48417300 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48417300 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-72388000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-41041000 usd
us-gaap Net Income Loss
NetIncomeLoss
-203239000 usd
us-gaap Net Income Loss
NetIncomeLoss
-117838000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
304000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1203000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
304000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1203000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-17000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72084000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41042000 usd
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-204442000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-117855000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
496583000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10712000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
425000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-41041000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
466678000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
325734000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18518000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
377000 usd
CY2022Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
212000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
304000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-72388000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
612400000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
557058000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26562000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
913000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-17000 usd
us-gaap Net Income Loss
NetIncomeLoss
-117838000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
466678000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
422396000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
54041000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1679000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1341000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1203000 usd
us-gaap Net Income Loss
NetIncomeLoss
-203239000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
612400000 usd
us-gaap Net Income Loss
NetIncomeLoss
-203239000 usd
us-gaap Net Income Loss
NetIncomeLoss
-117838000 usd
us-gaap Depreciation
Depreciation
510000 usd
us-gaap Depreciation
Depreciation
344000 usd
swtx Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
845000 usd
swtx Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
745000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
54041000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
26562000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2210000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-687000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4065000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
301000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-256000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
449000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1162000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1148000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
13542000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8613000 usd
swtx Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-301000 usd
swtx Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-1039000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
19546000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-33000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-107363000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-81561000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8440000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
512000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
4200000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
0 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
67953000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
218863000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
220006000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
246786000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
139413000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27411000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1341000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1679000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
913000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
340404000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
913000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
372454000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-53237000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104526000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
147654000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
476980000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94417000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5580000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Nature Of Operations
NatureOfOperations
Nature of Operations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SpringWorks Therapeutics, Inc., together with its wholly-owned subsidiaries, collectively, the Company, is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The Company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two late-stage clinical trials, one registrational and one potentially registrational, in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. Two of the programs are late-stage clinical product candidates: nirogacestat and mirdametinib.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative operating cash flows since inception and had an accumulated deficit of $495.8 million and $292.5 million, and working capital of $607.8 million and $352.9 million, as of September 30, 2022 and December 31, 2021, respectively. The Company is subject to those risks associated with any biopharmaceutical company that has substantial expenditures for development. There can be no assurance that the Company’s development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, consultants and vendors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">At-the-Market Program</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 25, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC serving as sales agent, or the Agent, with respect to an at-the-market offering program, or ATM Program, under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share, or Common Stock, having an aggregate offering price of up to $200 million through the Agent. Any shares offered and sold in the ATM Program are issued pursuant to the Company’s registration statement on Form S-3, or the Registration Statement, filed with the Securities and Exchange Commission, or SEC, on October 6, 2020, the prospectus supplement relating to the ATM Program filed with the SEC on February 25, 2021, and any applicable additional prospectus supplements related to the ATM Program that form a part of the Registration Statement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended September 30, 2022, the Company sold 2,247,500 shares of Common Stock under the ATM Program for gross proceeds of $69.7 million, less commissions and other fees of $1.9 million for net proceeds of $67.8 million. As of September 30, 2022, approximately $130.3 million remains available under the ATM Program. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Private Placements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2022, the Company and certain accredited investors, or the Investors, entered into a securities purchase agreement pursuant to which the Company agreed to sell and issue to the Investors in a private placement transaction, or the Private Placement, an aggregate of 8,650,520 shares of Common Stock at a purchase price of $26.01 per share. In connection with the Private Placement, the Company received gross proceeds of approximately $225 million, and after deducting commissions and offering costs, net proceeds were approximately $216.8 million. In connection with the Private Placement, the Company and the Investors also entered into a registration rights agreement, dated September 7, 2022, providing for the registration for resale of the shares. The shares were registered for resale pursuant to the Registration Statement and the prospectus supplement relating to the shares filed with the SEC on September 26, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2022, we entered into an expanded global, non-exclusive license and collaboration agreement with GSK, plc, formerly GlaxoSmithKline plc, or GSK, for nirogacestat in combination with belantamab mafodotin (belamaf) and, concurrent with the execution of such agreement, we entered into a stock purchase agreement, or the Stock Purchase Agreement, with an affiliate of GSK, Glaxo Group Limited, or GGL, under which GGL agreed to purchase from the Company in a private placement transaction 2,050,819 shares of Common Stock for an aggregate purchase price of approximately $75.0 million, or $36.57 per share. The shares were sold at a 25% premium to the volume-weighted average share price of the Company’s Common Stock for a specified 30-day period prior to entering into the Stock Purchase Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had cash, cash equivalents and marketable securities of $651.9 million and $432.7 million as of September 30, 2022 and December 31, 2021, respectively. Based on the Company's cash, cash equivalents and marketable securities as of September 30, 2022, management estimates that its current liquidity will enable it to meet operating expenses through at least twelve months after the date that these financial statements are issued.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 11, 2020, the World Health Organization designated the outbreak of the disease associated with the novel strain of coronavirus known as COVID-19 as a global pandemic. This disease continues to spread, including emerging variant strains of COVID-19, in the areas in which the Company operates. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work. Uncertainty with respect to the economic impacts of the pandemic has introduced significant volatility in the financial markets. The global pandemic caused by COVID-19 (including the impact of emerging variant strains of the COVID-19 virus and stagnant vaccination rates) did not have significant impacts on the Company's financial condition, results of operations or cash flows during the periods presented. While the extent to which the ongoing COVID-19 pandemic impacts the Company’s future results will depend on future developments, the pandemic and associated impacts, including the duration, spread and intensity of the pandemic (including any resurgences), the impact of emerging variant strains of the COVID-19 virus and the rollout of COVID-19 vaccines, all of which remain uncertain and difficult to predict, could result in a material impact to the Company’s future financial condition, results of operations and cash flows.</span></div>
CY2022Q3 swtx Number Of Clinical Trials
NumberOfClinicalTrials
2 trial
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-495800000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-292500000 usd
CY2022Q3 swtx Working Capital
WorkingCapital
607800000 usd
CY2021Q4 swtx Working Capital
WorkingCapital
352900000 usd
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
651900000 usd
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
432700000 usd
us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and the valuation of stock-based compensation awards. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known.
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
315000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
328770000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
177029000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1515000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
175514000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
329082000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18518000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10712000 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8086000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1108000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12233000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12081000 usd
CY2022Q3 swtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
14023000 usd
CY2021Q4 swtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
10069000 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4947000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2120000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
39289000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25378000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
54041000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26562000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
103000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1262000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1155000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1184000 usd
CY2022Q3 swtx Lessee Operating Lease Liability Payments Due After Three Year
LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear
2881000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6585000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
852000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5733000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9993259 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6947045 shares

Files In Submission

Name View Source Status
0001773427-22-000045-index-headers.html Edgar Link pending
0001773427-22-000045-index.html Edgar Link pending
0001773427-22-000045.txt Edgar Link pending
0001773427-22-000045-xbrl.zip Edgar Link pending
ex104gskamendedandrestat.htm Edgar Link pending
ex104gskamendedandrestat001.jpg Edgar Link pending
ex104gskamendedandrestat002.jpg Edgar Link pending
ex104gskamendedandrestat003.jpg Edgar Link pending
ex104gskamendedandrestat004.jpg Edgar Link pending
ex104gskamendedandrestat005.jpg Edgar Link pending
ex104gskamendedandrestat006.jpg Edgar Link pending
ex104gskamendedandrestat007.jpg Edgar Link pending
ex104gskamendedandrestat008.jpg Edgar Link pending
ex104gskamendedandrestat009.jpg Edgar Link pending
ex104gskamendedandrestat010.jpg Edgar Link pending
ex104gskamendedandrestat011.jpg Edgar Link pending
ex104gskamendedandrestat012.jpg Edgar Link pending
ex104gskamendedandrestat013.jpg Edgar Link pending
ex104gskamendedandrestat014.jpg Edgar Link pending
ex104gskamendedandrestat015.jpg Edgar Link pending
ex104gskamendedandrestat016.jpg Edgar Link pending
ex104gskamendedandrestat017.jpg Edgar Link pending
ex104gskamendedandrestat018.jpg Edgar Link pending
ex104gskamendedandrestat019.jpg Edgar Link pending
ex104gskamendedandrestat020.jpg Edgar Link pending
ex104gskamendedandrestat021.jpg Edgar Link pending
ex104gskamendedandrestat022.jpg Edgar Link pending
ex104gskamendedandrestat023.jpg Edgar Link pending
ex104gskamendedandrestat024.jpg Edgar Link pending
ex104gskamendedandrestat025.jpg Edgar Link pending
ex104gskamendedandrestat026.jpg Edgar Link pending
ex104gskamendedandrestat027.jpg Edgar Link pending
ex104gskamendedandrestat028.jpg Edgar Link pending
ex104gskamendedandrestat029.jpg Edgar Link pending
ex104gskamendedandrestat030.jpg Edgar Link pending
ex104gskamendedandrestat031.jpg Edgar Link pending
ex104gskamendedandrestat032.jpg Edgar Link pending
ex104gskamendedandrestat033.jpg Edgar Link pending
ex104gskamendedandrestat034.jpg Edgar Link pending
ex104gskamendedandrestat035.jpg Edgar Link pending
ex104gskamendedandrestat036.jpg Edgar Link pending
ex104gskamendedandrestat037.jpg Edgar Link pending
ex104gskamendedandrestat038.jpg Edgar Link pending
ex104gskamendedandrestat039.jpg Edgar Link pending
ex104gskamendedandrestat040.jpg Edgar Link pending
ex104gskamendedandrestat041.jpg Edgar Link pending
ex104gskamendedandrestat042.jpg Edgar Link pending
ex104gskamendedandrestat043.jpg Edgar Link pending
ex104gskamendedandrestat044.jpg Edgar Link pending
ex104gskamendedandrestat045.jpg Edgar Link pending
ex104gskamendedandrestat046.jpg Edgar Link pending
ex104gskamendedandrestat047.jpg Edgar Link pending
ex104gskamendedandrestat048.jpg Edgar Link pending
ex104gskamendedandrestat049.jpg Edgar Link pending
ex104gskamendedandrestat050.jpg Edgar Link pending
ex104gskamendedandrestat051.jpg Edgar Link pending
ex104gskamendedandrestat052.jpg Edgar Link pending
ex104gskamendedandrestat053.jpg Edgar Link pending
ex104gskamendedandrestat054.jpg Edgar Link pending
ex104gskamendedandrestat055.jpg Edgar Link pending
ex104gskamendedandrestat056.jpg Edgar Link pending
ex104gskamendedandrestat057.jpg Edgar Link pending
ex104gskamendedandrestat058.jpg Edgar Link pending
ex104gskamendedandrestat059.jpg Edgar Link pending
ex104gskamendedandrestat060.jpg Edgar Link pending
ex104gskamendedandrestat061.jpg Edgar Link pending
ex104gskamendedandrestat062.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
swtx-20220930.htm Edgar Link pending
swtx-20220930.xsd Edgar Link pending
swtx-20220930xex311.htm Edgar Link pending
swtx-20220930xex312.htm Edgar Link pending
swtx-20220930xex321.htm Edgar Link pending
swtx-20220930xex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
swtx-20220930_cal.xml Edgar Link unprocessable
swtx-20220930_lab.xml Edgar Link unprocessable
swtx-20220930_def.xml Edgar Link unprocessable
swtx-20220930_pre.xml Edgar Link unprocessable
swtx-20220930_htm.xml Edgar Link completed